Kenvue Inc. (NYSE:KVUE) Plans $0.21 Quarterly Dividend

Kenvue Inc. (NYSE:KVUE) announced a quarterly dividend on Wednesday, April 16th, RTT News reports. Investors of record on Wednesday, May 14th will be given a dividend of 0.205 per share on Wednesday, May 28th. This represents a $0.82 dividend on an annualized basis and a yield of 3.60%.

Kenvue has a payout ratio of 66.7% indicating that its dividend is sufficiently covered by earnings. Analysts expect Kenvue to earn $1.24 per share next year, which means the company should continue to be able to cover its $0.82 annual dividend with an expected future payout ratio of 66.1%.

Kenvue Trading Down 0.7 %

Shares of KVUE stock opened at $22.76 on Thursday. The stock has a market capitalization of $43.67 billion, a PE ratio of 42.94, a P/E/G ratio of 2.62 and a beta of 1.02. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The business has a 50-day moving average of $22.80 and a 200 day moving average of $22.40. Kenvue has a 1-year low of $17.67 and a 1-year high of $24.46.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, sell-side analysts anticipate that Kenvue will post 1.14 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently issued reports on KVUE shares. Redburn Atlantic began coverage on shares of Kenvue in a research report on Thursday, April 10th. They set a “neutral” rating and a $23.50 price target on the stock. Citigroup raised their target price on Kenvue from $21.00 to $22.00 and gave the company a “neutral” rating in a research note on Monday. Barclays dropped their price objective on shares of Kenvue from $23.00 to $22.00 and set an “equal weight” rating on the stock in a research note on Monday. UBS Group cut their price objective on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research report on Friday, February 7th. Finally, Evercore ISI started coverage on shares of Kenvue in a research note on Monday, March 24th. They issued an “in-line” rating and a $25.00 target price on the stock. Eight equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, Kenvue presently has a consensus rating of “Hold” and an average target price of $24.42.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.